HALOZYME THERAPEUTICS, INC. — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Stock-Based Comp↑+44.6% +$5M
$17M
SBC Allocated Expense↑+44.6% +$5M
$17M
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).